RT Journal Article
SR Electronic
T1 <em>De novo</em> variants in <em>SNAP25</em> cause an early-onset developmental and epileptic encephalopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20095141
DO 10.1101/2020.05.11.20095141
A1 Klöckner, Chiara
A1 Sticht, Heinrich
A1 Zacher, Pia
A1 Popp, Bernt
A1 Bakker, Dewi P.
A1 Barwick, Katy
A1 Bonfert, Michaela V.
A1 Brilstra, Eva H.
A1 Care4Rare Canada Consortium
A1 Chung, Wendy K.
A1 Clarke, Angus J.
A1 Devine, Patrick
A1 Friedman, Jennifer
A1 Gates, Alyssa
A1 Horvath, Gabriella
A1 Keller-Ramey, Jennifer
A1 Keren, Boris
A1 Kurian, Manju A.
A1 Lee, Virgina
A1 Leppig, Kathleen A.
A1 Lundgren, Johan
A1 McDonald, Marie T.
A1 McTague, Amy
A1 Mefford, Heather C.
A1 Mignot, Cyril
A1 Mikati, Mohamad A.
A1 Nava, Caroline
A1 Raymond, F. Lucy
A1 Sampson, Julian R.
A1 Sanchis-Juan, Alba
A1 Shashi, Vandana
A1 Shieh, Joseph T.C.
A1 Shinawi, Marwan
A1 Slavotinek, Anne
A1 Stödberg, Tommy
A1 Stong, Nicholas
A1 Sullivan, Jennifer A.
A1 Taylor, Ashley C.
A1 Toler, Tomi L.
A1 van den Bogaard, Marie-José
A1 van der Crabben, Saskia N.
A1 van Gassen, Koen
A1 van Jaarsveld, Richard H.
A1 Van Ziffle, Jessica
A1 Wadley, Alexandrea F.
A1 Wagner, Matias
A1 Wortmann, Saskia B.
A1 Møller, Rikke S.
A1 Lemke, Johannes R.
A1 Platzer, Konrad
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20095141.abstract
AB Purpose This study aims to provide the first comprehensive description of the phenotypic and genotypic spectrum of SNAP25 developmental and epileptic encephalopathy (SNAP25- DEE) by reviewing newly identified and previously reported individuals.Methods Individuals harboring heterozygous missense or truncating variants in SNAP25 were assembled through collaboration with international colleagues, matchmaking platforms and literature review. For each individual, detailed phenotyping, classification and structural modeling of the identified variant was performed.Results The cohort comprises 20 individuals with (likely) pathogenic de novo variants in SNAP25. Intellectual disability and early-onset epilepsy were identified as the core symptoms of SNAP25-DEE, with recurrent findings of movement disorders, cortical visual impairment and brain atrophy. Structural modeling for all variants predicted possible functional defects concerning SNAP25 or impaired interaction with other components of the SNARE complex.Conclusion We provide a first comprehensive description of SNAP25-DEE with intellectual disability and early onset epilepsy mostly occurring before the age of two years. These core symptoms and additional recurrent phenotypes show an overlap to genes encoding other components or associated proteins of the SNARE complex such as STX1B, STXBP1 or VAMP2. Thus, these findings advance the concept of a group of neurodevelopmental disorders that may be termed “SNAREopathies”.Competing Interest StatementJKR is an employee of GeneDx, Inc. The other authors declare no conflicts of interest.Funding StatementWork on individual 5 was supported in part by grants from SFARI and the JPB Foundation. AM, KB and MAK are funded by the NIHR GOSH BRC. Individual 7 was enrolled in the NIHR BioResource research study, supported by the Cambridge Biomedical Research Centre and the National Institute for Health Research (NIHR) for the NIHR BioResource (grant number RG65966). Funding for the Duke Genome Sequencing Clinic which is supported by the Duke University Health System. Individual V6 was enrolled in Care4Rare Canada Consortium, funded by Genome Canada, Ontario Genomics Institute (OGI-147), Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, BC Children’s Hospital Foundation, BC Children’s Hospital Research Institute, BC Provincial Health Services Authority, Genome Quebec, and Children’s Hospital of Eastern Ontario Foundation. This study makes use of data generated by the DECIPHER Consortium. A full list of centres who contributed to the generation of the data is available from https://decipher.sanger.ac.uk/ and via email from decipher{at}sanger.ac.uk. Funding for the project was provided by the Wellcome Trust. R.S.M. was supported by a grant from the Lundbeck Foundation (R277-2018-802). Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number U01HG009599.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and methods are reported in the article and in the supplement.